Therapeutic Efficacy of Kangfuxin Liquid Combined with PPIs in Gastric Ulcer
Joint Authors
Zou, Jun-Bo
Zhang, Xiao-Fei
Shi, Ya-Jun
Tai, Jia
Wang, Yu
Liang, Yu-Lin
Wang, Fang
Cheng, Jiang-Xue
Wang, Jing
Guo, Dong-Yan
Source
Evidence-Based Complementary and Alternative Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-13, 13 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-09-30
Country of Publication
Egypt
No. of Pages
13
Main Subjects
Abstract EN
Objective.
To evaluate the clinical efficacy and safety of Kangfuxin liquid (KFX) combined with proton pump inhibitors (PPIs) in the treatment of gastric ulcer (GU).
Materials and Methods.
Electronic databases including PubMed, Wanfang, CNKI, VIP, Embase, Cochrane Library, and CBM were examined for appropriate articles without language limitations on key words before March 10, 2019.
RevMan 5.3 software was applied to execute outcome assessment and finish the meta-analysis.
Results.
22 articles involving 2,024 patients with a gastric ulcer were selected.
Total efficacy rate and efficacy rate of gastroscopy were significantly enhanced for the combination of KFX with PPIs compared to those of PPI treatment alone (OR = 6.95, 95% CI: 4.87, 9.91, P<0.00001; OR = 2.96, 95% CI: 1.98, 4.42, P<0.00001, respectively).
Same results were found for different PPIs in combination on total efficacy rate, respectively.
The combination also significantly reduced the adverse events (OR = 0.39, 95% CI: 0.22, 0.70, P=0.002).
In addition, KFX combined with PPI could suppress the inflammation (MD = −6.11, 95% CI: −7.45, −4.77, P<0.00001), reduce the recurrence rate (OR = 0.31, 95% CI: 0.14, 0.70, P=0.005), and enhance the clearance rate of Helicobacter pylori (HP, OR = 3.76, 95% CI: 1.80, 7.87, P=0.0004).
It seemed like the combination would influence immune function by increasing levels of T-lymphocyte subsets CD4 and CD8 but not CD3 (MD = 2.40, 95% CI: 1.25, 3.55, P<0.0001); MD = 25.72, 95% CI: 14.55, 36.90, P<0.00001; MD = 0.72, 95% CI: −0.66, 2.09, P=0.31, respectively).
Conclusion.
KFX combined with PPIs in treatment of patients with GU could improve the total efficacy rate and efficacy rate of gastroscopy and reduce adverse events and the recurrence rate.
However, the results of this study should be handled with care due to the limitations.
Several rigorous RCTs are in need to confirm these findings.
American Psychological Association (APA)
Zou, Jun-Bo& Zhang, Xiao-Fei& Shi, Ya-Jun& Tai, Jia& Wang, Yu& Liang, Yu-Lin…[et al.]. 2019. Therapeutic Efficacy of Kangfuxin Liquid Combined with PPIs in Gastric Ulcer. Evidence-Based Complementary and Alternative Medicine،Vol. 2019, no. 2019, pp.1-13.
https://search.emarefa.net/detail/BIM-1148502
Modern Language Association (MLA)
Zou, Jun-Bo…[et al.]. Therapeutic Efficacy of Kangfuxin Liquid Combined with PPIs in Gastric Ulcer. Evidence-Based Complementary and Alternative Medicine No. 2019 (2019), pp.1-13.
https://search.emarefa.net/detail/BIM-1148502
American Medical Association (AMA)
Zou, Jun-Bo& Zhang, Xiao-Fei& Shi, Ya-Jun& Tai, Jia& Wang, Yu& Liang, Yu-Lin…[et al.]. Therapeutic Efficacy of Kangfuxin Liquid Combined with PPIs in Gastric Ulcer. Evidence-Based Complementary and Alternative Medicine. 2019. Vol. 2019, no. 2019, pp.1-13.
https://search.emarefa.net/detail/BIM-1148502
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1148502